Intrafractional stability of MR-guided online adaptive SBRT for prostate cancer.
MR-guided radiotherapy
Online adaptation
Plan-of-the-day
Prostate SBRT
Journal
Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111
Informations de publication
Date de publication:
26 Sep 2021
26 Sep 2021
Historique:
received:
22
03
2021
accepted:
15
09
2021
entrez:
27
9
2021
pubmed:
28
9
2021
medline:
27
1
2022
Statut:
epublish
Résumé
MR-guided online adaptive stereotactic body radiation therapy (SBRT) for prostate cancer aims to reduce toxicity by full compensation of interfractional uncertainties. However, the process of online adaptation currently takes approximately 45 min during which intrafractional movements remain unaccounted for. This study aims to analyze the dosimetric benefit of online adaptation and to evaluate its robustness over the duration of one treatment fraction. Baseline MR-scans at a MR-linear accelerator were acquired for ten healthy male volunteers for generation of mock-prostate SBRT plans with a dose prescription of 5 × 7.25 Gy. On a separate day, online MR-guided adaptation (ViewRay A dosimetric benefit of online MR-guided adaptive re-planning was observed in 90% of volunteers. The median D The dosimetric benefit of MR-guided online adaptation for prostate SBRT was robust over 45 min in all volunteers. However, intrafractional uncertainties became dosimetrically relevant at 60 min and we therefore recommend verification imaging before delivery of MR-guided online adapted SBRT.
Sections du résumé
BACKGROUND
BACKGROUND
MR-guided online adaptive stereotactic body radiation therapy (SBRT) for prostate cancer aims to reduce toxicity by full compensation of interfractional uncertainties. However, the process of online adaptation currently takes approximately 45 min during which intrafractional movements remain unaccounted for. This study aims to analyze the dosimetric benefit of online adaptation and to evaluate its robustness over the duration of one treatment fraction.
METHODS
METHODS
Baseline MR-scans at a MR-linear accelerator were acquired for ten healthy male volunteers for generation of mock-prostate SBRT plans with a dose prescription of 5 × 7.25 Gy. On a separate day, online MR-guided adaptation (ViewRay
RESULTS
RESULTS
A dosimetric benefit of online MR-guided adaptive re-planning was observed in 90% of volunteers. The median D
CONCLUSION
CONCLUSIONS
The dosimetric benefit of MR-guided online adaptation for prostate SBRT was robust over 45 min in all volunteers. However, intrafractional uncertainties became dosimetrically relevant at 60 min and we therefore recommend verification imaging before delivery of MR-guided online adapted SBRT.
Identifiants
pubmed: 34565439
doi: 10.1186/s13014-021-01916-0
pii: 10.1186/s13014-021-01916-0
pmc: PMC8474766
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
189Informations de copyright
© 2021. The Author(s).
Références
Int J Radiat Oncol Biol Phys. 2007 Oct 1;69(2):419-25
pubmed: 17513059
Radiat Oncol. 2019 Sep 2;14(1):158
pubmed: 31477122
Pract Radiat Oncol. 2018 Mar - Apr;8(2):116-122
pubmed: 29329996
Phys Med Biol. 2019 Apr 04;64(7):07NT02
pubmed: 30794995
Radiat Oncol. 2020 Mar 23;15(1):69
pubmed: 32248826
Lancet Oncol. 2019 Nov;20(11):1531-1543
pubmed: 31540791
Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):1903-11
pubmed: 21470786
Int J Radiat Oncol Biol Phys. 2007 Mar 15;67(4):1088-98
pubmed: 17187940
Radiother Oncol. 2019 Oct;139:83-86
pubmed: 31431369
Radiother Oncol. 2018 May;127(2):206-212
pubmed: 29551231
Lancet Oncol. 2016 Aug;17(8):1047-1060
pubmed: 27339115
Lancet. 2019 Aug 3;394(10196):385-395
pubmed: 31227373
Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):912-9
pubmed: 17459605
Urol Oncol. 2017 Feb;35(2):59-68
pubmed: 27395453
Int J Radiat Oncol Biol Phys. 2003 Dec 1;57(5):1285-91
pubmed: 14630263
Radiother Oncol. 2020 Oct;151:88-94
pubmed: 32622779
Acta Oncol. 2015;54(9):1474-82
pubmed: 26206517
Int J Radiat Oncol Biol Phys. 2019 Jul 15;104(4):933-941
pubmed: 30928360
Radiat Med. 2005 Feb;23(1):14-24
pubmed: 15786747
Cureus. 2019 Dec 24;11(12):e6457
pubmed: 32025388
Int J Radiat Oncol Biol Phys. 2006 Jun 1;65(2):528-34
pubmed: 16690435
Radiat Oncol. 2013 May 13;8:118
pubmed: 23668632
Radiother Oncol. 2019 Jun;135:86-90
pubmed: 31015175
JAMA Netw Open. 2019 Feb 1;2(2):e188006
pubmed: 30735235
Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):206-14
pubmed: 12007961
Melanoma Res. 2016 Aug;26(4):387-94
pubmed: 27223498
Pract Radiat Oncol. 2014 Sep-Oct;4(5):e203-e212
pubmed: 25194106
Int J Radiat Oncol Biol Phys. 2004 Sep 1;60(1):30-9
pubmed: 15337537
Int J Radiat Oncol Biol Phys. 2019 Jul 15;104(4):778-789
pubmed: 30959121
Int J Radiat Oncol Biol Phys. 2019 Jun 1;104(2):334-342
pubmed: 30721721